DENTSPLY SIRONA (NASDAQ:XRAY) Upgraded to “Hold” at Zacks Research

DENTSPLY SIRONA (NASDAQ:XRAY) was upgraded by research analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a research report issued to clients and investors on Monday,Zacks.com reports.

A number of other brokerages have also issued reports on XRAY. Mizuho increased their price target on DENTSPLY SIRONA from $14.00 to $16.00 and gave the company a “neutral” rating in a research note on Monday. Robert W. Baird raised their target price on DENTSPLY SIRONA from $12.00 to $14.00 and gave the company a “neutral” rating in a research note on Friday, February 27th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of DENTSPLY SIRONA in a report on Wednesday, January 21st. Bank of America raised shares of DENTSPLY SIRONA from a “neutral” rating to a “buy” rating and upped their price target for the company from $13.00 to $17.00 in a report on Thursday, February 19th. Finally, UBS Group reduced their price objective on shares of DENTSPLY SIRONA from $17.00 to $16.00 and set a “buy” rating for the company in a research report on Tuesday, February 3rd. Three research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, DENTSPLY SIRONA currently has a consensus rating of “Hold” and a consensus target price of $14.42.

DENTSPLY SIRONA Stock Performance

XRAY stock opened at $13.30 on Monday. The company has a 50-day simple moving average of $12.52 and a 200 day simple moving average of $12.47. The company has a market capitalization of $2.66 billion, a P/E ratio of -4.43, a PEG ratio of 1.68 and a beta of 0.97. The company has a quick ratio of 1.03, a current ratio of 1.51 and a debt-to-equity ratio of 1.50. DENTSPLY SIRONA has a fifty-two week low of $9.85 and a fifty-two week high of $17.18.

DENTSPLY SIRONA (NASDAQ:XRAY) last released its quarterly earnings results on Thursday, February 26th. The medical instruments supplier reported $0.27 EPS for the quarter, missing analysts’ consensus estimates of $0.28 by ($0.01). The company had revenue of $961.00 million for the quarter, compared to the consensus estimate of $926.40 million. DENTSPLY SIRONA had a positive return on equity of 18.85% and a negative net margin of 16.25%.The firm’s quarterly revenue was up 6.2% compared to the same quarter last year. During the same quarter last year, the firm posted $0.26 earnings per share. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. Sell-side analysts predict that DENTSPLY SIRONA will post 1.84 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, Director Gregory T. Lucier acquired 22,445 shares of DENTSPLY SIRONA stock in a transaction on Tuesday, March 3rd. The stock was bought at an average cost of $14.03 per share, with a total value of $314,903.35. Following the completion of the purchase, the director owned 50,000 shares of the company’s stock, valued at $701,500. This represents a 81.46% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 0.52% of the company’s stock.

Institutional Investors Weigh In On DENTSPLY SIRONA

A number of institutional investors have recently bought and sold shares of the business. Virtu Financial LLC acquired a new position in shares of DENTSPLY SIRONA in the 4th quarter valued at about $302,000. Compound Planning Inc. purchased a new position in DENTSPLY SIRONA during the fourth quarter valued at approximately $117,000. Invesco Ltd. increased its stake in DENTSPLY SIRONA by 101.1% in the 4th quarter. Invesco Ltd. now owns 1,063,523 shares of the medical instruments supplier’s stock valued at $12,156,000 after buying an additional 534,714 shares during the period. Michels Family Financial LLC lifted its position in DENTSPLY SIRONA by 8.9% in the 4th quarter. Michels Family Financial LLC now owns 41,989 shares of the medical instruments supplier’s stock worth $480,000 after buying an additional 3,422 shares in the last quarter. Finally, Alpine Woods Capital Investors LLC acquired a new stake in shares of DENTSPLY SIRONA during the 4th quarter valued at $680,000. 95.70% of the stock is currently owned by institutional investors and hedge funds.

More DENTSPLY SIRONA News

Here are the key news stories impacting DENTSPLY SIRONA this week:

• Positive Sentiment: Director buying: Gregory T. Lucier significantly increased his stake in Dentsply Sirona, purchasing 27,555 shares on March 2 at ~$14.24 and 22,445 shares on March 3 at ~$14.03 (bringing his reported holdings to ~50,000 shares). Large insider purchases are often viewed as a bullish signal of management confidence. SEC Form 4
• Positive Sentiment: Barrington Research raised its price target to $17 and maintained an “outperform” rating — a bullish analyst action that implies meaningful upside from current levels and can support buying interest. Barrington Research PT Raise
• Neutral Sentiment: Mizuho raised its price target to $16 but kept a “neutral” rating — a PT lift that helps sentiment but the unchanged rating tempers the positive impact. Mizuho PT Update TickerReport
• Neutral Sentiment: Investor access: Management will present at the Leerink Partners Global Healthcare Conference on March 10 — a scheduled investor event that provides an opportunity for management to update guidance and interact with analysts (near-term catalyst if new commentary or data are released). Conference Notice
• Neutral Sentiment: Analyst coverage/targets: Smaller media posts also reported price-target bumps (AmericanBankingNews noted PTs raised to $13 and $14). These incremental upgrades help sentiment but are mixed in magnitude. PT to $13 PT to $14
• Neutral Sentiment: Fundamental note: A Zacks piece flagged international revenue trends as an area to watch; investors assessing XRAY should consider geographic growth dynamics versus company guidance/analyst models. Zacks Analysis
• Neutral Sentiment: Short-interest data appears anomalous (reports show zero shares / NaN changes), suggesting a reporting error rather than a genuine short-squeeze or relief — treat the short-interest updates cautiously. (No reliable link; data appears inconsistent in the filings.)

About DENTSPLY SIRONA

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.